Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total

P 2 (4)

Trial Status

Recruiting5

Not Yet Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials

NCT04924075Phase 2RecruitingPrimary

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT07680205Phase 2Recruiting

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT07621146Not Yet Recruiting

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

NCT07167329Phase 2Recruiting

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

NCT06683846Phase 2RecruitingPrimary

Ivonescimab in the Treatment of Multiple Advanced Tumors

Showing all 6 trials